Home Newsfeeds IMV Q3 EPS $(0.11) Up From $(0.13) YoY

IMV Q3 EPS $(0.11) Up From $(0.13) YoY

IMV (NASDAQ:IMV) reported quarterly losses of $(0.11) per share. This is a 15.38 percent increase over losses of $(0.13) per share from the same period last year.

byBenzinga Newsdesk

November 10, 2022

1 minute read

IMV (NASDAQ:IMV) reported quarterly losses of $(0.11) per share. This is a 15.38 percent increase over losses of $(0.13) per share from the same period last year.

Stephens & Co. Reinstates Overweight on Orange County Bancorp, Announces $50 Price Target

By Benzinga Newsdesk

December 9, 9:39 AM

Stephens & Co. analyst Matt Breese reinstates Orange County Bancorp (NASDAQ:OBT) with a Overweight and announces $50 price target.

OBT

Citigroup Upgrades WestRock to Buy, Lowers Price Target to $32

By Benzinga Newsdesk

March 20, 7:57 AM

Citigroup analyst Anthony Pettinari upgrades WestRock (NYSE:WRK) from Neutral to Buy and lowers the price target from $35 to $32.

WRK

News

Is Amazon Set To See More Competition This Fall? FedEx Announces Launch Of Data-Driven E-Commerce Platform

By Benzinga Neuro

January 14, 9:50 PM

FedEx Corp. (NYSE:FDX) has announced a data-driven E-commerce platform. The logistics goliath is calling it fdx. What Happened:…

AMZN

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI As Preferred Category 1 Regimen For First-Line Treatment Of Cancer Of The Nasopharynx

By Benzinga Newsdesk

December 11, 9:36 AM

– NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy; LOQTORZI

CHRS

IMV Q3 EPS $(0.11) Up From $(0.13) YoY

Related Posts

Stephens & Co. Reinstates Overweight on Orange County Bancorp, Announces $50 Price Target

Citigroup Upgrades WestRock to Buy, Lowers Price Target to $32

Is Amazon Set To See More Competition This Fall? FedEx Announces Launch Of Data-Driven E-Commerce Platform

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI As Preferred Category 1 Regimen For First-Line Treatment Of Cancer Of The Nasopharynx